Simris Alg

SIMRIS GROUP CONFIRMS STRATEGIC DIRECTION AND ADVANCES TWO AMANITIN-BASED ADC PROGRAMS TOWARD THE CLINIC

Simris Group AB (publ) (“Simris” or the “Company”) confirms its strategy to develop amanitin-derived novel payloads to overcome treatment resistance in both liquid and solid tumors. Under strengthened specialist leadership, the Company will focus on advancing two proprietary Antibody-Drug Conjugate (“ADC”) programs into clinical development by late 2027 or early 2028.

SIMRIS GROUP INTERIM REPORT JANUARY-JUNE 2026

SIMRIS GROUP APPOINTS BIOTECHNOLOGY EXPERT DR. TIFFANY J. VORA AS STRATEGIC ADVISOR

Simris Group AB today announced the appointment of Dr. Tiffany J. Vora as a Strategic Advisor.

SIMRIS GROUP AB APPOINTS ADC EXPERT PROFESSOR ANDREAS PAHL AS CHIEF EXECUTIVE OFFICER OF ITS SUBSIDIARY SIMRIS BIOLOGICS GMBH

Simris Group AB (SIMRIS B) today announced the appointment of Professor Andreas Pahl as Chief Executive Officer of Simris Biologics GmbH, its wholly owned subsidiary based in Berlin, Germany. Professor Pahl will begin his assignment immediately. Simris Biologics develops next-generation antibody-drug conjugate (ADC) payloads based on nature-derived technologies.

A holder of warrants in Simris Group AB (publ) has declared his intention to exercise 3.3 million warrants amounting to total proceeds of EUR 15,000

Simris Group AB (publ) ("Simris Group" or the "Company") has today received information from a holder of warrants of series 2026/2027 in Simris Group that he intends to exercise 3.3 million warrants at the subscription price of SEK 0.05 per class B share, amounting to total proceeds of EUR 15,000 before transaction costs.

Holders of warrants in Simris Group AB (publ) have declared their intention to exercise 220 million warrants amounting to total proceeds of MEUR 1

Simris Group AB (publ) ("Simris Group" or the "Company") has today received information from certain holders of warrants of series 2025/2027 and series 2026/2027 in Simris Group that they intend to exercise 220 million warrants at the subscription price of SEK 0.05 per class B share, amounting to total proceeds of MEUR 1 before transaction costs.

Bulletin from Simris Group AB’s annual general meeting

Simris Group AB (publ), reg. no. 556841–9187 (the "Company"), held its annual general meeting on 24 June 2026. Below follows a summary of the resolutions that were passed at the general meeting

Correction: Notice of the Annual General Meeting of Simris Group AB (publ)

English version follow after the Swedish version.

Notice of Extraordinary General Meeting of Simris Group AB (publ)

English version follow after the Swedish version.

SIMRIS GROUP INTERIM REPORT JANUARY-MARCH 2026

Simris Group Advances Asset Divestment Process with Two Prospective Buyers

Simris Group AB (Simris or the Company) today announces progress in its strategic divestment process for its microalgae production facility in Hammenhög, Sweden. Simris has entered into a Memorandum of Understanding (MoU) with a second strategic prospective buyer based in Asia. Under this new MoU, the prospective acquirer has been granted a 45-day exclusivity period to conduct comprehensive due diligence and submit a firm and binding offer by 26 June 2026. In addition, the first strategic prospective buyer, has reaffirmed its interest in acquiring the Company's microalgae production assets and is actively pursuing capital to fund the transaction.

SIMRIS GROUP PUBLISHES ITS ANNUAL REPORT FOR 2025

Simris Group AB has published its annual report for the 2025 financial year.